Sivik Global Healthcare LLC Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Sivik Global Healthcare LLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,000 shares of the biotechnology company's stock, valued at approximately $1,493,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Signaturefd LLC raised its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after buying an additional 80 shares during the period. Bessemer Group Inc. grew its stake in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Searle & CO. purchased a new stake in Ascendis Pharma A/S during the 2nd quarter worth about $205,000. Rhumbline Advisers raised its position in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after purchasing an additional 143 shares in the last quarter. Finally, Pursue Wealth Partners LLC purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $217,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Wedbush raised shares of Ascendis Pharma A/S to a "strong-buy" rating in a research report on Monday, November 4th. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a report on Wednesday, October 23rd. Evercore ISI increased their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a research note on Tuesday, September 17th. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. Finally, TD Cowen boosted their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a "buy" rating in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $195.92.

Ascendis Pharma A/S Stock Down 1.4 %

NASDAQ ASND traded down $1.75 during mid-day trading on Thursday, hitting $124.28. The stock had a trading volume of 974,853 shares, compared to its average volume of 445,610. The company has a 50 day simple moving average of $132.04 and a 200 day simple moving average of $132.86. The company has a market cap of $7.54 billion, a price-to-earnings ratio of -13.54 and a beta of 0.66. Ascendis Pharma A/S has a 52-week low of $90.13 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analysts' expectations of $94.74 million. As a group, equities analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.